15:44
2026-06-21
cryptobriefing.com
generative-ai
Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery
Absci Corporation dosed the first patients in a Phase 1/2a trial of ABS-201, an AI-designed antibody for hair loss, achieving a concept-to-clinic timeline of approximately 24 months. The trial, named …